{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-194511","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.524629+00:00","generated_at":"2026-05-17T08:32:59.886673+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study","bullets":["200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels","Individual during acute phase response showed 20.6 µM total AAT and 10.3 µM M-AAT, first demonstration of restored physiological production","Single 400 mg dose achieved 12.8 µM total AAT and 5.3 µM M-AAT; monthly dosing supported","GSK holds exclusive global license for WVE-006; Wave eligible for up to $525M milestones plus royalties","Data support monthly or less frequent subcutaneous dosing; 400 mg multidose cohort data expected Q1 2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-194511","json":"https://secwatch.observer/filing/0001193125-25-194511.json","markdown":"https://secwatch.observer/filing/0001193125-25-194511.md","text":"https://secwatch.observer/filing/0001193125-25-194511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/0001193125-25-194511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/d67509d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T08:32:59.886673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}